Explore the words cloud of the NeutroCure project. It provides you a very rough idea of what is the project "NeutroCure" about.
The following table provides information about the project.
FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG
|Coordinator Country||Germany [DE]|
|Total cost||2˙999˙998 €|
|EC max contribution||2˙999˙998 € (100%)|
1. H2020-EU.1.2.1. (FET Open)
|Duration (year-month-day)||from 2020-01-01 to 2024-12-31|
Take a look of project's partnership.
|1||FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG||DE (ERLANGEN)||coordinator||629˙000.00|
|2||UNIVERSITATSKLINIKUM ERLANGEN||DE (ERLANGEN)||participant||640˙000.00|
|3||UNIVERSITY OF SURREY||UK (GUILDFORD)||participant||410˙998.00|
|4||CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)||ES (MADRID)||participant||400˙000.00|
|5||LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO||UA (LVIV)||participant||400˙000.00|
|6||REDOXIS AB||SE (LUND)||participant||400˙000.00|
|7||INSTITUT GUSTAVE ROUSSY||FR (VILLEJUIF)||participant||120˙000.00|
Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (“cure”) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUTROCURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEUTROCURE" are provided by the European Opendata Portal: CORDIS opendata.